A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Newave Pharmaceutical, Inc.
Start Date
October 22, 2021
End Date
October 17, 2026
Administered By
Duke Cancer Institute
Awarded By
Newave Pharmaceutical, Inc.
Start Date
October 22, 2021
End Date
October 17, 2026